Update on treatment strategies for optimization of final adult height in children with Congenital adrenal hyperplasia

Pediatric Endocrinology Reviews

Volumn 10, Issue 1, 2012, Pages 164-173

  Javed, Asma ^a   Lteif, Aida ^a   Kumar, Seema ^a  

^a MAYO CLINIC   (United States)

Author keywords

Anti androgen; Aromatase inhibitor; CAH; Final height; GnRH analogs; Growth hormone; Precocious puberty; Target height

Indexed keywords

ANTIANDROGEN; AROMATASE INHIBITOR; GLUCOCORTICOID; GONADORELIN AGONIST; GROWTH HORMONE; HYDROCORTISONE; DRUG DERIVATIVE; GONADORELIN; HUMAN GROWTH HORMONE; STEROID 21 MONOOXYGENASE;

ANDROGEN RELEASE; BODY GROWTH; BODY HEIGHT; BONE AGE; CALCIUM ABSORPTION; CHILDHOOD DISEASE; CONGENITAL ADRENAL HYPERPLASIA; CONTINUOUS INFUSION; CORTICOSTEROID THERAPY; DRUG DELIVERY SYSTEM; EPIPHYSIS; FINAL ADULT HEIGHT; GROWTH HORMONE RELEASE; HORMONAL REGULATION; HORMONAL THERAPY; HUMAN; HYDROCORTISONE RELEASE; HYPERANDROGENISM; HYPERCORTISOLISM; IATROGENIC DISEASE; META ANALYSIS (TOPIC); PRECOCIOUS PUBERTY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SALT WASTING; SEX DIFFERENCE; STEROID 21 MONOOXYGENASE DEFICIENCY; SUSTAINED RELEASE FORMULATION; TALL STATURE; ADULT; CHILD; DRUG COMBINATION; TREATMENT OUTCOME;

ADRENAL HYPERPLASIA, CONGENITAL; ADULT; ANDROGEN ANTAGONISTS; AROMATASE INHIBITORS; BODY HEIGHT; CHILD; DRUG THERAPY, COMBINATION; GLUCOCORTICOIDS; GONADOTROPIN-RELEASING HORMONE; HUMAN GROWTH HORMONE; HUMANS; PUBERTY, PRECOCIOUS; STEROID 21-HYDROXYLASE; TREATMENT OUTCOME;

MLCS; MLOWN;

EID: 84875607781     PISSN: 15654753     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (105)

1. Pang, S., Clark, A, Congenital adrenal hyperplasia due to 21-hydroxylase deficiency: Newborn screening and its relationship to the diagnosis and treatment of the disorder. Screening, 1993; 2:105
2. BL, T., Newborn screening for congenital adrenal hyperplasia. Endocrinol Metab Clin North Am, 2001 ; 30 ((1) ):15
3. New, M. I., Extensive clinical experience: nonclassical 21-hydroxylase deficiency. Journal of Clinical Endocrinology 6 Metabolism 2006; 91 (11):4205-4214
4. Bonfig, W. and H. P. Schwarz, Growth pattern of untreated boys with simple virilizing congenital adrenal hyperplasia indicates relative androgen insensitivity during the first six months of life. Hormone research in pdiatrics, 2011. 75 (4):264-268
5. Bonfig W, S. H., Schwarz HP., Growth patterns in the first three years of life in children with classical congenital adrenal hyperplasia diagnosed by newborn screening and treated with low doses of hydrocortisone. Horm Res Paediatr, 2011; 75 (1):32-37
6. Brunelli, V. L., et al., Final height in congenital adrenal hyperplasia due to 21-hydroxylase deficiency: the Italian experience. Journal of Pediatric Endocrinology, 2003; 16 Suppl 2:277-283
7. Lim, Y. J. B., J A. Warne, G L, Adrenal 21-hydroxylase deficiency in childhood: 25 years' experience. Journal of Paediatrics ft Child Health, 1995; 31 ((3)):222-227
8. Van der Kamp, H. J., et al., Longitudinal analysis of growth and puberty in 21-hydroxylase deficiency patients. Archives of Disease in Childhood, 2002; 87 (2):139-144
9. Kolouskova, S., et al., (Growth and adult height in patients with congenital adrenal hyperplasia). Casopis Lekaru Ceskych, 1995; 134 (21):689-91
10. Kamoun, M., et al., Long term outcome in adult patients with congenital adrenal hyperplasia due to 21 hydroxylase deficiency. Hormone Research in Paediatrics, 2011; 76:132
11. Manoli, I., et al., Early growth, pubertal development, body mass index and final height of patients with congenital adrenal hyperplasia: factors influencing the outcome. Clinical Endocrinology, 2002; 57 (5):669-676
12. Migeon, C. J. and A. B. Wisniewski, Congenital adrenal hyperplasia owing to 21-hydroxylase deficiency. Growth, development, and therapeutic considerations. Endocrinology & Metabolism Clinics of North America, 2001; 30 (1): 193-206
13. Muthusamy, K., et at., Adult height in patients with congenital adrenal hyperplasia: A systematic review and metaanalysis. Journal of Clinical Endocrinology and Metabolism, 2010; 95 (9):4161-4172
14. Eugster, E. A., et at., Height outcome in congenital adrenal hyperplasia caused by 21-hydroxylase deficiency: a meta-analysis. Journal of Pediatrics, 2001; 138 (1):26-32
15. Merke, D. and M. Kabbani, Congenital adrenal hyperplasia: epidemiology, management and practical drug treatment. Paediatric Drugs, 2001. 3 (8):599-611
16. Solimán, AT., et al., Congenital adrenal hyperplasia complicated by central precocious puberty: linear growth during infancy and treatment with gonadotropin-reteasing hormone analog. Metabolism: Clinical a Experimental, 1997; 46 (5):513-517
17. New, M. I., et at., Growth and final height in classical and nonclassical 21-hydroxylase deficiency. Journal of Endocrinological Investigation, 1989. 12 (8 Suppl3):91-95
18. Nguyen, A. T., J. J. Brown, and G. L. Warne, Growth in congenital adrenal hyperplasia. Indian Journal of Pediatrics, 2006; 73 (1):89-93
19. Trinh L, N. S., New Ml, Lin-Su K., Growth and pubertal characteristics in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Pediatr Endocrinol Metab, 2007. 20 (8):883-891
20. Eyal, O., et al., Final height of subjects with non-classical 21-hydroxylase deficiency by age at initiation of glucocorticoid therapy and genotype. Endocrine Reviews. Conference: 93rd Annual Meeting and Expo of the Endocrine Society, ENDO, 2011. 32 (3 Meeting Abstracts).
21. Trapp, CM. and S. E. Oberfield, Recommendations for treatment of nonclassic congenital adrenal hyperplasia (NCCAH): an update. Steroids, 2012; 77 (4):342-346
22. Bonfig, W., et al., Reduced final height outcome in congenital adrenal hyperplasia under prednisone treatment: deceleration of growth velocity during puberty. Journal of Clinical Endocrinology & Metabolism, 2007. 92 (5):1635-1639
23. Dorr, H. G., Growth in patients with classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Hormone Research, 2007; 68:Suppl 5:93-99
24. Hoepffner, W., et al., Patients with classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency can achieve their target height: the Leipzig experience. Hormone Research, 2008; 70 (1):42-50
25. Girgis, R. and J. S. Winter, The effects of glucocorticoid replacement therapy on growth, bone mineral density, and bone turnover markers in children with congenital adrenal hyperplasia. Journal of Clinical Endocrinology & Metabolism, 1997; 82 (12):3926-3929
26. Li., L, Congenital adrenal hyperplasia. Pediatr Rev, 2000; 21:159-170
27. Brook, C. G., Zachmann, M., Prader, A., Murset, G., Experience with long-term therapy in congenital adrenal hyperplasia. J. Pediatr, 1974; 85 (1):12-19
28. DiMartino-Nardi, J., Stoner, E., O'Connell, A., New, M. I.,, The effect of treatment of final height in classical congenital adrenal hyperplasia. Acta Endocrinol. Suppl., 1986. 279:305-314
29. Dunkel, L., Use of aromatase inhibitors to increase final height. Molecular a Cellular Endocrinology, 2006; 254-255:207-216
30. New, M. I., An update of congenital adrenal hyperplasia. Annals of the New York Academy of Sciences, 2004. 1038:14-43
31. Muirhead, S., et al., Indicators of adult height outcome in classical 21-hydroxylase deficiency congenital adrenal hyperplasia. Journal of Pediatrics, 2002; 141 (2):247-252
32. Aycan, I., et al., Experience with long-term glucocorticoid treatment in congenital adrenal hyperplasia: growth pattern compared with genetic height potential. Journal of Pediatric Endocrinology 2006; 19 (3):245-251
33. Cutler GB Jr, L. L., Congenital adrenal hyperplasia due to 21-hydroxylase deficiency. N Engl J Med, 1990; 323:1806-1813
34. Speiser, P. W., New therapies for congenital adrenal hyperplasia. Current Opinion in Endocrinology and Diabetes, 2003; 10 (1):32-36
35. Kaufmann S, J. K., Wehrenberg WB, Culler FL Inhibition by prednisone of growth hormone (GH) response to GH-releasing hormone in normal men. J Clin Endocrinol Metab 1988; 67:1258-1261
36. Savage, M. O., et at., Growth abnormalities associated with adrenal disorders and their management. Hormone Research, 2001; 56:Suppl 1:19-23
37. Rasat, R., E. A. Espiner, and G. D. Abbott, Growth patterns and outcomes in congenital adrenal hyperplasia; effect of chronic treatment regimens. New Zealand Medical Journal, 1995; 108: (1005):311-314
38. I. N. Silva, D. F. O. J. u., C. J. R. Simal, M. B. Viana, and A. J. Chagas, Morning steroid profile in children with congenital adrenal hyperplasia under different hydrocortisone schedules. Indian Journal of Pediatrics, 1994. 61 (4):341-346
39. Ricardo P. P. Moreira, I. A. A. L. J., Larissa G. Gomes, Laura C. Kaupert, Joäo Massud Filho, Berenice B. Mendonca. and Tänia A. S. S. Bachegal, Pharmacogenetics of glucocorticoid replacement could optimize the treatment of congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Clinics (Sao Paulo), 2011; 66 (8):1361 -1365
40. Aziz, M., et at., Pubertal growth and adult height in patients with classical congenital adrenal hyperplasia. Hormone Research in Paediatrics, 2010; 74:9-10
41. Speiser, P. W., Medical treatment of classic and nonclassic congenital adrenal hyperplasia, in Hormonal and Genetic Basis of Sexual Differentiation Disorders and Hot Topics in Endocrinology: Proceedings of the 2nd World Conference, M. I. New and J. L. Simpson, Editors. Springer New York: 233 Springer Street, New York NY 10013-1578, United States. 2011; 41-45
42. Punthakee Z, L. L., PolychronakosC, Prednisolone in the treatment of adrenal insufficiency: a re-evaluation of relative potency. J Pediatr Endocrinol Metab, 2003; 143:402-405
43. Rivkees SA, C. J., Dexamethasone treatment of virilizing congenital adrenal hyperplasia: the ability to achieve normal growth. Pediatrics 2000; 106:767-773
44. Gussinye, M., et at., (Adult height, pattern of growth and pubertal development in patients with congenital adrenal hyperplasia, salt losing form). Medicina Clinica, 1997; 108 (3):87-90
45. Silva, I. N., et at., Randomised controlled trial of growth effect of hydrocortisone in congenital adrenal hyperplasia. Archives of Disease in Childhood, 1997; 77 (3):214-218
46. Grigorescu-Sido A, B. M., Schulze E, Duncea I, Heinrich U., Growth analysis in patients with 21-hydroxylase deficiency influence of glucocorticoiddosage, age at diagnosis, phenotype and genotype on growth and height outcome. Horm Res. 2003; 60 ((2)):84-90
47. Balsamo, A., et al., Birth length and weight in congenital adrenal hyperplasia according to the different phenotypes. European Journal of Pediatrics, 2006; 165 (6):380-383
48. Bonfig W, P. S., Schmidt H, Pagel P, Knorr D, Schwarz HP, Hydrocortisone dosing during puberty in patients with classical congenital adrenal hyperplasia: an evidence-based recommendation. J Clin Endocrinol Metab, 2009. 94 ((10)):3882-3888
49. Lopes, L. A., et at., Should we monitor more closely the dosage of 9 alpha-fluorohydrocortisone in salt-losing congenital adrenal hyperplasia? Journal of Pediatric Endocrinology, 1998; 11 (6):733-737
50. Speiser PW, A. R., Baskin LS, Ghizzoni L, Hensle TW, Merke DP, Meyer- Bahlburg HF, Milter WL, Montori VM, Oberfield SE, Ritzen M, White PC; Endocrine Society., Congenital Adrenal Hyperplasia Due to Steroid 21-Hydroxylase Deficiency: An Endocrine Society Clinical Practice Guideline. (J Clin Endocrinol Metab 2010; 95:4133-4160
51. Hindmarsh, P. C., Management of the child with congenital adrenal hyperplasia. Best Practice and Research: Clinical Endocrinology and Metabolism, 2009; 23 (2):193-208
52. Appan, S., P. C. Hindmarsh, and CG. Brook, Monitoring treatment in congenital adrenal hyperplasia. Archives of Disease in Childhood, 1989. 64 (9):1235-1239
53. Merke DP, CD., Calis KA, Keil MF, Chrousos GP J Clin Endocrinol Metab 86:441-445
54. Hydrocortisone suspension and hydrocortisone tablets are not bioequivalent in the treatment of children with congenital adrenal hyperplasia. J Clin Endocrinol Metab, 2001; 86:441-445
55. PC, H., Management of the child with congenital adrenal hyperplasia. Best Pract Res Clin Endocrinol Metab, 2009; 23 (2):193-208
56. Clayton, G. W., Patterns of growth from birth to maturity in infants and children with congenital adrenal hyperplasia. Acta Endocrinologica Supplementum, 1986; 279:295-304
57. Gussinye, M., et al., Final height in patients with congenital adrenal hyperplasia. (Spanish) Talla Final En Pacientes Con Hiperplasia Suprarrenal Congenita. Endocrinologia, 1994; 41 (SUPPL 2):35-39
58. Stefan A. Wudy, M. F. H., and Thomas Remer, Sexual dimorphism in Cortisol secretion starts after age 10 in healthy children: urinary Cortisol metabolite excretion rates during growth American journal of Physiology: Endocrinology and Metabolism, 2007; 10
59. Charmandari E, H. P., Johnston A, Brook CG., Congenital adrenal hyperplasia due to 21-hydroxylase deficiency: alterations in Cortisol pharmacokinetics at puberty. Journal of Clinical Endocrinology Et Metabolism, 2001; 86 (6):2701-2708
60. Gasparini, N., et al., Growth pattern during the first 36 months of life in congenital adrenal hyperplasia (21-hydroxylase deficiency). Hormone Research, 1997; 47 (1):17-22
61. Young, M. C. and I. A. Hughes, Response to treatment of congenital adrenal hyperplasia in infancy. Archives of Disease in Childhood, 1990; 65 (4):441-444
62. Thilen A, W. K., Perry LA, Savage MO, Wedell A, Ritzen EM., Early growth is not increased in untreated moderately severe 21-hydroxylase deficiency. Acta Paediatr. 1995; 84 ((8)):894-898
63. Merke, D. P. and S. R. Bornstein, Congenital adrenal hyperplasia. Lancet, 2005. 365 (9477):2125-2136
64. Claahsen-van der Grinten HL, N. K., Borm GF, Otten BJ., Absence of increased height velocity in the first year of life in untreated children with simple virilizing congenital adrenal hyperplasia. J Clin Endocrinol Metab. 2006; 91: (4) ((4)):1205-1209
65. Jaaskelainen, J. and R. voutilainen, Growth of patients with 21-hydroxylase deficiency: an analysis of the factors influencing adult height. Pediatric Research, 1997; 41 (1):30-33
66. Mendes-dos-Santos, C. T., et at, Growth in patients with the salt- wasting form of congenital adrenal hyperplasia during the first two years of life. Revista Brasileira de Saude Materno Infantil, 2009; 9 (4):415-421
67. Stikkelbroeck NM, V. t. H.-G. B., Hermus AR, Otten BJ, Van't Hof MA., Growth inhibition by glucocorticoid treatment in salt wasting 21-hydroxylase deficiency: in early infancy and (pre)puberty. J Clin Endocrinol Metab, 2003; 88 (8): 3525-3530
68. Charmandari E, H. P., Johnston A, BrookCG, Congenital adrenal hyperplasia due to 21-hydroxylase deficiency: alterations in Cortisol pharmacokinetics at puberty. J Clin Endocrinol Metab 86:2701-2708.
69. Premawardhana, L. D., et al., Longer term outcome in females with congenital adrenal hyperplasia (CAH): the Cardiff experience. Clinical Endocrinology, 1997; 46 (3): 327-332
70. Weintrob N, D. Z., Sprecher E, Galatzer A, Pertzelan A., Non-classical 21-hydroxylase deficiency in infancy and childhood: the effect of time of initiation of therapy on puberty and final height. Eur J Endocrinol, 1997; 136 ((2)):188-195
71. MG, F., Recent advances in the diagnosis and management of congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Human Reproduction Update, 2004; 10 ((6)):469-485
72. Debono M, G. C., Rostami-Hodjegan A, Huatan H, Campbell MJ, Newell-Price J, Darzy K, Merke DP, Arlt W, Ross RJ, Modified-release hydrocortisone to provide circadian Cortisol profiles. J Clin Endocrinol Metab 2009; 94:1548-1554.
73. Weitzman ED, F. D., Nogeire C, Roffwarg H, Gallagher TF, Hellman L, Twenty-four hour pattern of the episodic secretion of Cortisol in normal subjects. J Clin Endocrinol Metab., 1971; 33:14-22
74. Bryan SM, H. J., Hindmarsh PC, Management of altered hydrocortisone pharmacokinetics in a boy with congenital adrenal hyperplasia using a continuous subcutaneous hydrocortisone infusion. J Clin Endocrinol Metab., 2009; 94:3477-3480
75. Merza Z, R.-H. A., Memmott A, Doane A, Ibbotson V, Newell-Price J, Tucker GT, Ross RJ, Orcadian hydrocortisone infusions in patients with adrenal insufficiency and congenital adrenal hyperplasia. Clin Endocrinol (Oxf), 2006; 65:45-50
76. Tuli G, R. I., Einaudi S, di Gianni V, Tessaris D, Gioia E, Lala R, Cerutti R, Continuous subcutaneous hydrocortisone infusion (CSHI) in a young adolescent with congenital adrenal hyperplasia (CAH). J Pediatr Endocrinol Metab. 2011 ; 24 (7-8):561-3.
77. Tabarin, M.-L. N. a. A., News for adrenal insufficiency. Annales d'Endocrinologie, 2008. 69 (1): S44-S52
78. Verma S, S. N., Kim MS, Nieman LK, Ravindran S, Calis KA, Arlt W, Ross RJ, Merke DP, A pharmacokinetic and pharmacodynamic study of delayed- and extended-release hydrocortisone (Chronocort ™) versus conventional hydrocortisone (Cortef™) in the treatment of congenital adrenal hyperplasia. Clin Endocrinol (Oxf). 72:441-447
79. G. Johannsson, R. B., A. G. Nilsson, H. Lennernas, T. Hedner, and S. Skrtic, Improving glucocorticoid replacement therapy using a novel modified-retease hydrocortisone tablet: a pharmacokinetic study. European Journal of Endocrinology, 2009; 161 (1):119-130
80. Lin-Su, K., et al., Final adult height in children with congenital adrenal hyperplasia treated with growth hormone. Journal of Clinical Endocrinology & Metabolism, 2011; 96 (6):1710-1717
81. Lin-Su, K., et al., Treatment with growth hormone and luteinizing hormone releasing hormone analog improves final adult height in children with congenital adrenal hyperplasia. Journal of Clinical Endocrinology & Metabolism, 2005; 90 (6):3318-3325
82. Pescovitz, O. H., et al., True precocious puberty complicating congenital adrenal hyperplasia: treatment with a luteinizing hormone- releasing hormone analog. Journal of Clinical Endocrinology & Metabolism, 1984; 58 (5):857-861
83. Gallagher, M. P., L. S. Levine, and S. E. Oberfield, A review of the effects of therapy on growth and bone mineralization in children with congenital adrenal hyperplasia. Growth Hormone & Igf Research, 2005; 15SupplA:26-30
84. Ghizzoni, L., et al., Spontaneous Cortisol and growth hormone secretion interactions in patients with nonclassic 21-hydroxylase deficiency (NCCAH) and control children. Journal of Clinical Endocrinology & Metabolism, 1996; 81 (2):482-487
85. Massart F, F. G., Harrell JC, Saggese G, Growth outcome during GnRH agonist treatments for slowly progressive central precocious puberty. Neuroendocrinology., 2009; 90 ((3)):307-314
86. Longui, C. A., et al., Near-final height in patients with congenital adrenal hyperplasia treated with combined therapy using GH and GnRHa. Arquivos Brasileiros de Endocrinologia e Metabologia, 2011; 55 (8):661-664
87. Carel, J. C., et al., Consensus statement on the use of gonadotropin- releasing hormone analogs in children. Pediatrics, 2009; 123 (4):752-762
88. Pescovitz, O. H., et al., The NIH experience with precocious puberty: diagnostic subgroups and response to short-term luteinizing hormone releasing hormone analogue therapy. Journal of Pediatrics, 1986; 108 (1):47-54
89. Clemons, R. D., et al., Long-term effectiveness of depot gonadotropin- releasing hormone analogue in the treatment of children with central precocious puberty. American Journal of Diseases of Children, 1993. 147 (6):653-657
90. Sasano, H., Uzuki, M., Sawai, T, et al., Aromatase in human bonetissue. J. Bone Miner. Res., 1997; 12{ (9)): 1416-1423
91. El Ouahabi, H., et al., Treatment with anti-androgens and aromatase inhibitors in addition to low hydrocortisone doses in children with congenital adrenal hyperplasia (CAH). Hormone Research in Paediatrics, 2011; 76:130
92. Dunket, L, Update on the role of aromatase inhibitors in growth disorders. Hormone Research, 2009; 71 (SUPPL 1):57-63
93. Eyal O., L. Naugolny, and N. Weintrob, (The use of aromatase inhibitors in children). Harefuah, 2009. 148 (12):825-30, 855
94. Merke, D. P., et at., Flutamide, testolactone, and reduced hydrocortisone dose maintain normal growth velocity and bone maturation despite elevated androgen levels in children with congenital adrenal hyperplasia. Journal of Clinical Endocrinology & Metabolism, 2000; 85 (3):1114-1120
95. S. Wickman, T. S., and L. Dunkel, The role of sex steroids in the regulation of insulin sensitivity and serum lipid concentrations during male puberty: a prospective study with a P450-aromatase inhibitor. European Journal of Endocrinology, 2002; 146 (3):339-342
96. S. Wickman, I. S. A. C. Ankarberg-Lindgren, E. Norjavaara, and L. Dunkel, A specific aromatase inhibitor and potentiat increase in adult height in boys with delayed puberty: a randomised controlled trial. Lancet, 2001; 357 (9270):1743-1748
97. Mauras, N., Strategies for maximizing growth in puberty in children with short stature. Endocrinology and Metabolism Clinics of North America, 2009; 38 ((3)):613-624
98. S. Wickman, E. K., L. Dunkel, Effects of suppression of estrogen action by the p450 aromatase inhibitor letrozole on bone mineral density and bone turnover in pubertal boys, J. Clin. Endocrinol. Metab., 2003; 88 ((8)):3785-3793
99. Shulman, D. I., et at., Use of aromatase inhibitors in children and adolescents with disorders of growth and adolescent development. Pediatrics, 2008; 121 (4):975-983
100. Charmandari, E., et al., Flutamide decreases Cortisol clearance in patients with congenital adrenal hyperplasia. Journal of Clinical Endocrinology & Metabolism, 2002; 87 (7):3197-200
101. Fukushima DK, S. M., Levin J Further studies on the effect of flutamide on Cortisol metabolism. Steroids 1980; 35:209-217
102. Loechner KJ, M. J., Calikoglu AS., Alternative strategies for the treatment of classical congenital adrenal hyperplasia: pitfalls and promises. Int J Pediatr Endocrinol., 2010. 670960. Epub 2010 Jun 24
103. Quintos, J. B., et al., Growth hormone therapy alone or in combination with gonadotropin-releasing hormone analog therapy to improve the height deficit in children with congenital adrenal hyperplasia. Journal of Clinical Endocrinology & Metabolism, 2001 ; 86 (4):1511-1517
104. Hero, M., et al., Circulating antiandrogenic activity in children with congenital adrenal hyperplasia during peroral flutamide treatment. Journal of Clinical Endocrinology & Metabolism, 2005; 90 (9):5141-5145
105. RP, S., Back to basics: early diagnosis and compliance improve final height outcome in congenital adrenal hyperplasia. J Pediatr, 2001; 138 ((1)):3-5